Advertisement
U.S. markets close in 5 hours 30 minutes

ARGX Dec 2024 410.000 call

OPR - OPR Delayed Price. Currency in USD
93.510.00 (0.00%)
As of 12:53PM EST. Market open.
Full screen
Previous Close93.51
Open93.51
Bid117.50
Ask122.00
Strike410.00
Expire Date2024-12-20
Day's Range93.51 - 93.51
Contract RangeN/A
Volume1
Open Interest5
  • BioPharma Dive

    Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

    Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.

  • GlobeNewswire

    argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

    Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease